BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.

3031 Background: BOLD-100 is a first-in-class ruthenium-based anticancer agent in Phase 1b / 2 clinical development for the treatment of advanced gastrointestinal (GI) cancers in combination with FOLFOX. Being developed primarily as a combinational agent, BOLD-100 induces cellular stress through modulation of the unfolded protein response, production of reactive oxygen species and induction of DNA damage. BOLD-100 demonstrates …